{
    "paper_id": "PMC7110575",
    "metadata": {
        "title": "\u00c9volution des techniques de pr\u00e9paration des produits sanguins labiles (PSL)\u00a0: inactivation des pathog\u00e8nes dans les PSL",
        "authors": [
            {
                "first": "C.",
                "middle": [],
                "last": "Naegelen",
                "suffix": "",
                "email": "christian.naegelen@efs.sante.fr",
                "affiliation": {}
            },
            {
                "first": "H.",
                "middle": [],
                "last": "Isola",
                "suffix": "",
                "email": "herve.isola@efs-alsace.fr",
                "affiliation": {}
            },
            {
                "first": "D.",
                "middle": [],
                "last": "Dernis",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "J.-P.",
                "middle": [],
                "last": "Maurel",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "R.",
                "middle": [],
                "last": "Tardivel",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "S.",
                "middle": [],
                "last": "Bois",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "C.",
                "middle": [],
                "last": "Vignoli",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "J.-P.",
                "middle": [],
                "last": "Cazenave",
                "suffix": "",
                "email": null,
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "Des progr\u00e8s significatifs en mati\u00e8re de r\u00e9duction de risque de transmission d\u2019agents pathog\u00e8nes chez les receveurs ont \u00e9t\u00e9 observ\u00e9s au cours des deux derni\u00e8res d\u00e9cennies. Notamment dans les pays industrialis\u00e9s o\u00f9 le risque transfusionnel est relativement faible gr\u00e2ce aux syst\u00e8mes de s\u00e9lection des donneurs et aux m\u00e9thodes de d\u00e9tection permettant ainsi la destruction des produits issus de dons pr\u00e9sentant un r\u00e9sultat positif aux diff\u00e9rents marqueurs s\u00e9rologiques test\u00e9s. Jusqu\u2019\u00e0 pr\u00e9sent, la strat\u00e9gie a donc \u00e9t\u00e9, d\u2019une part, de renforcer la s\u00e9lection des donneurs et, d\u2019autre part, de d\u00e9velopper et de mettre en place des m\u00e9thodes de d\u00e9tection des agents pathog\u00e8nes [1], [2], [3], [4]. N\u00e9anmoins, il persiste encore un risque r\u00e9siduel de transmission de ces agents par transfusion [5]. De 2005 \u00e0 2007, le risque r\u00e9siduel calcul\u00e9 est de 1 pour 2 950 000 transfusions pour la transmission du VIH, de 1 pour 8 300 000 pour le HTLV, de 1 pour 12 500 000 pour le virus de l\u2019h\u00e9patite C (VHC) et de 1 pour 1 000 000 pour le virus de l\u2019h\u00e9patite B (VHB) [6]. Outre ces risques r\u00e9siduels, les incidents transfusionnels par contamination bact\u00e9rienne, bien que faibles, persistent [5]. En effet, le nombre d\u2019infections bact\u00e9riennes transmises par transfusion (IBTT) en France \u00e9tait de 12 en l\u2019an 2000, tous PSL confondus, dont deux de grade quatre (d\u00e9c\u00e8s au cours ou au d\u00e9cours de la transfusion) impliquant des concentr\u00e9s de plaquettes. En 2007, le nombre d\u2019IBTT \u00e9tait de neuf dont trois de grade quatre impliquant \u00e0 nouveau des concentr\u00e9s plaquettaires [7]. Le rapport annuel 2006 d\u2019h\u00e9movigilance de l\u2019Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire et des produits de sant\u00e9 (Afssaps) rapporte \u00e9galement pour 2006 des donn\u00e9es comparables, avec sept cas, dont trois cas impliquant des concentr\u00e9s de globules rouges (GR) (tous de grade 1 : absence de menace vitale imm\u00e9diate ou \u00e0 long terme) et quatre cas impliquant des concentr\u00e9s de plaquettes d\u2019aph\u00e9r\u00e8se (CPA) (tous de grade 3 : menace vitale imm\u00e9diate) [8]. Enfin, les derni\u00e8res ann\u00e9es ont mis en \u00e9vidence la n\u00e9cessit\u00e9 de pr\u00e9venir le risque des agents pathog\u00e8nes \u00e9mergents qui peuvent poser de graves probl\u00e8mes transfusionnels dans les diff\u00e9rentes r\u00e9gions du monde, tels que le West Nile Virus, virus du syndrome respiratoire aigu s\u00e9v\u00e8re (Sras) ou le virus du Chikungunya [5]. Ainsi, au vu du nombre important d\u2019agents pathog\u00e8nes connus, de l\u2019\u00e9mergence continue de nouveaux pathog\u00e8nes, la mise en place syst\u00e9matique de nouvelles m\u00e9thodes de d\u00e9tection n\u2019est pas envisageable. Les proc\u00e9d\u00e9s d\u2019inactivation constituent alors une nouvelle strat\u00e9gie contre les agents pathog\u00e8nes connus, \u00e9mergents et ceux encore non-identifi\u00e9s [1], [2], [3], [4], [5]. En effet, bien que la s\u00e9curit\u00e9 transfusionnelle en soit am\u00e9lior\u00e9e, la d\u00e9tection des agents pathog\u00e8nes reste en effet une d\u00e9marche r\u00e9active car les m\u00e9thodes de d\u00e9tection sont en g\u00e9n\u00e9ral d\u00e9velopp\u00e9es une fois le pathog\u00e8ne identifi\u00e9. L\u2019inactivation des agents pathog\u00e8nes est au contraire une d\u00e9marche proactive permettant d\u2019\u00e9liminer les \u00e9ventuels agents pathog\u00e8nes pr\u00e9sents dans les produits. La plupart des m\u00e9thodes existantes et en cours de d\u00e9veloppement agissent sur les acides nucl\u00e9iques de ces pathog\u00e8nes et permettent ainsi l\u2019inactivation d\u2019un large spectre d\u2019agents pathog\u00e8nes pr\u00e9sents dans les produits sanguins. Cependant, de telles m\u00e9thodes ne sont mises en place une fois leur efficacit\u00e9 et leur absence de toxicit\u00e9 d\u00e9montr\u00e9es [1], [2], [3], [4].",
            "cite_spans": [
                {
                    "start": 667,
                    "end": 670,
                    "mention": "[1]",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 672,
                    "end": 675,
                    "mention": "[2]",
                    "ref_id": "BIBREF11"
                },
                {
                    "start": 677,
                    "end": 680,
                    "mention": "[3]",
                    "ref_id": "BIBREF22"
                },
                {
                    "start": 682,
                    "end": 685,
                    "mention": "[4]",
                    "ref_id": "BIBREF33"
                },
                {
                    "start": 782,
                    "end": 785,
                    "mention": "[5]",
                    "ref_id": "BIBREF44"
                },
                {
                    "start": 1046,
                    "end": 1049,
                    "mention": "[6]",
                    "ref_id": "BIBREF52"
                },
                {
                    "start": 1170,
                    "end": 1173,
                    "mention": "[5]",
                    "ref_id": "BIBREF44"
                },
                {
                    "start": 1544,
                    "end": 1547,
                    "mention": "[7]",
                    "ref_id": "BIBREF53"
                },
                {
                    "start": 1987,
                    "end": 1990,
                    "mention": "[8]",
                    "ref_id": "BIBREF54"
                },
                {
                    "start": 2306,
                    "end": 2309,
                    "mention": "[5]",
                    "ref_id": "BIBREF44"
                },
                {
                    "start": 2655,
                    "end": 2658,
                    "mention": "[1]",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 2660,
                    "end": 2663,
                    "mention": "[2]",
                    "ref_id": "BIBREF11"
                },
                {
                    "start": 2665,
                    "end": 2668,
                    "mention": "[3]",
                    "ref_id": "BIBREF22"
                },
                {
                    "start": 2670,
                    "end": 2673,
                    "mention": "[4]",
                    "ref_id": "BIBREF33"
                },
                {
                    "start": 2675,
                    "end": 2678,
                    "mention": "[5]",
                    "ref_id": "BIBREF44"
                },
                {
                    "start": 3414,
                    "end": 3417,
                    "mention": "[1]",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 3419,
                    "end": 3422,
                    "mention": "[2]",
                    "ref_id": "BIBREF11"
                },
                {
                    "start": 3424,
                    "end": 3427,
                    "mention": "[3]",
                    "ref_id": "BIBREF22"
                },
                {
                    "start": 3429,
                    "end": 3432,
                    "mention": "[4]",
                    "ref_id": "BIBREF33"
                }
            ],
            "section": "Introduction",
            "ref_spans": []
        },
        {
            "text": "Historiquement, les techniques physiques furent les premi\u00e8res m\u00e9thodes disponibles et mises en \u0153uvre en vue de s\u00e9curiser et de purifier les produits sanguins labiles.",
            "cite_spans": [],
            "section": "G\u00e9n\u00e9ralit\u00e9s ::: Les techniques physiques ::: M\u00e9canisme d\u2019action des m\u00e9thodes d\u2019inactivation des agents pathog\u00e8nes dans les PSL",
            "ref_spans": []
        },
        {
            "text": "M\u00eame si peu d\u2019\u00e9tudes sont disponibles, il a \u00e9t\u00e9 \u00e9tabli que l\u2019\u00e9limination du plasma par lavages cons\u00e9cutifs ou d\u00e9plasmatisation, \u00e9tudi\u00e9e dans le cadre de la r\u00e9duction virale, est d\u2019une efficacit\u00e9 limit\u00e9e. Une r\u00e9duction de 99,999 % du plasma contenu dans les concentr\u00e9s globulaires par lavages permet de r\u00e9duire au maximum de 2 log la charge virale [9].",
            "cite_spans": [
                {
                    "start": 347,
                    "end": 350,
                    "mention": "[9]",
                    "ref_id": "BIBREF55"
                }
            ],
            "section": "G\u00e9n\u00e9ralit\u00e9s ::: Les techniques physiques ::: M\u00e9canisme d\u2019action des m\u00e9thodes d\u2019inactivation des agents pathog\u00e8nes dans les PSL",
            "ref_spans": []
        },
        {
            "text": "Les techniques de cryoconservation suivies d\u2019une d\u00e9cong\u00e9lation appliqu\u00e9es aux concentr\u00e9s de GR permettent d\u2019obtenir une d\u00e9plasmatisation et une r\u00e9duction de l\u2019ordre de 2 \u00e0 3 log des leucocytes. L\u2019efficacit\u00e9 de ce proc\u00e9d\u00e9 a \u00e9t\u00e9 rapport\u00e9e par plusieurs \u00e9tudes cliniques qui ont montr\u00e9es une diminution du risque de transmission du cytom\u00e9galovirus (CMV) [10].",
            "cite_spans": [
                {
                    "start": 351,
                    "end": 355,
                    "mention": "[10]",
                    "ref_id": "BIBREF1"
                }
            ],
            "section": "G\u00e9n\u00e9ralit\u00e9s ::: Les techniques physiques ::: M\u00e9canisme d\u2019action des m\u00e9thodes d\u2019inactivation des agents pathog\u00e8nes dans les PSL",
            "ref_spans": []
        },
        {
            "text": "Apparue dans les ann\u00e9es 1985, la filtration pour d\u00e9leucocytation des produits sanguins labiles est un proc\u00e9d\u00e9 syst\u00e9matiquement appliqu\u00e9 en France sur les produits cellulaires depuis 1998 et depuis 2001 pour le plasma.",
            "cite_spans": [],
            "section": "G\u00e9n\u00e9ralit\u00e9s ::: Les techniques physiques ::: M\u00e9canisme d\u2019action des m\u00e9thodes d\u2019inactivation des agents pathog\u00e8nes dans les PSL",
            "ref_spans": []
        },
        {
            "text": "Les performances des dispositifs actuels permettent d\u2019obtenir une efficacit\u00e9 de d\u00e9leucocytation de l\u2019ordre de 4 log sur les produits cellulaires et de 5 log lorsque les techniques sont appliqu\u00e9es sp\u00e9cifiquement au plasma soit une contamination r\u00e9siduelle attendue inf\u00e9rieure \u00e0 1 \u00d7 106 leucocytes par poche (concentr\u00e9 globulaire, concentr\u00e9 plaquettaire) ou inf\u00e9rieure \u00e0 1 \u00d7 104 par litre (plasma).",
            "cite_spans": [],
            "section": "G\u00e9n\u00e9ralit\u00e9s ::: Les techniques physiques ::: M\u00e9canisme d\u2019action des m\u00e9thodes d\u2019inactivation des agents pathog\u00e8nes dans les PSL",
            "ref_spans": []
        },
        {
            "text": "Ces m\u00e9thodes sont donc efficaces pour la r\u00e9duction du risque de transmission des virus lymphotropes tels que le CMV, l\u2019Human T lymphotropic Virus I/II (HTLV-I/II), l\u2019Epstein Barr Virus (EBV). L\u2019efficacit\u00e9 de la d\u00e9leucocytation par filtration des produits sanguins labiles dans le cadre de la transmission du CMV est cliniquement \u00e9tablie [11], [12]. Il est d\u00e9montr\u00e9 que le risque de transmission de l\u2019HTLV-I/II est \u00e9galement r\u00e9duit par l\u2019utilisation de produits d\u00e9leucocyt\u00e9s [13]. De m\u00eame, la d\u00e9leucocytation permet de r\u00e9duire d\u2019un facteur de 4 log le nombre de copies de g\u00e9nome viral de l\u2019EBV apr\u00e8s filtration [14]. La technique de d\u00e9leucocytation pour le plasma a \u00e9t\u00e9 mise en place pour le plasma en 2001 par application du principe de pr\u00e9caution, notamment par rapport au prion, pathog\u00e8ne responsable du nouveau variant de la maladie de Creutzfeldt Jakob (PrPSc). L\u2019efficacit\u00e9 de cette technique n\u2019est actuellement pas d\u00e9montr\u00e9e.",
            "cite_spans": [
                {
                    "start": 337,
                    "end": 341,
                    "mention": "[11]",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 343,
                    "end": 347,
                    "mention": "[12]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 474,
                    "end": 478,
                    "mention": "[13]",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 610,
                    "end": 614,
                    "mention": "[14]",
                    "ref_id": "BIBREF5"
                }
            ],
            "section": "G\u00e9n\u00e9ralit\u00e9s ::: Les techniques physiques ::: M\u00e9canisme d\u2019action des m\u00e9thodes d\u2019inactivation des agents pathog\u00e8nes dans les PSL",
            "ref_spans": []
        },
        {
            "text": "D\u2019autres techniques comme l\u2019irradiation gamma, l\u2019irradiation aux UVB, aux UVC ont \u00e9t\u00e9 \u00e9tudi\u00e9es. L\u2019irradiation gamma a montr\u00e9 son efficacit\u00e9 sur les produits plasmatiques, mais les doses requises ne sont pas applicables aux cellules sans dommage pour celles-ci [15], [16]. Les techniques d\u2019irradiation aux UVB ou aux UVC r\u00e9alis\u00e9es dans des conditions op\u00e9ratoires pr\u00e9cises sur des suspensions plaquettaires ont montr\u00e9 leur efficacit\u00e9 sur certains virus ou bact\u00e9ries (UVB : 4 log de poliovirus, UVC : 4 log CPV, 4 log : Staphylococcus aureus), sans alt\u00e9ration fonctionnelle importante des cellules. Ces proc\u00e9d\u00e9s sont inefficaces sur d\u2019autres virus [17] (ex : UVC : 1 log VIH [18]).",
            "cite_spans": [
                {
                    "start": 260,
                    "end": 264,
                    "mention": "[15]",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 266,
                    "end": 270,
                    "mention": "[16]",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 645,
                    "end": 649,
                    "mention": "[17]",
                    "ref_id": "BIBREF8"
                },
                {
                    "start": 672,
                    "end": 676,
                    "mention": "[18]",
                    "ref_id": "BIBREF9"
                }
            ],
            "section": "G\u00e9n\u00e9ralit\u00e9s ::: Les techniques physiques ::: M\u00e9canisme d\u2019action des m\u00e9thodes d\u2019inactivation des agents pathog\u00e8nes dans les PSL",
            "ref_spans": []
        },
        {
            "text": "Ce sucre-alcool \u00e0 la dose utilis\u00e9e \u00e9vite de fa\u00e7on non sp\u00e9cifique la formation d\u2019agr\u00e9gats prot\u00e9iques (par exemple on constate par contr\u00f4le en Fast Protein Liquid Chromatography (FPLC) l\u2019absence de formation de polym\u00e8res d\u2019albumine ou de polym\u00e8res d\u2019immunoglobuline lorsque le plasma est chauff\u00e9 en sa pr\u00e9sence). De plus, le sorbitol permet d\u2019assurer une stabilisation significative (sup\u00e9rieure \u00e0 80 % en moyenne) de l\u2019activit\u00e9 coagulante de la plupart des facteurs de la coagulation dont le facteur VIII, le fibrinog\u00e8ne, le facteur V, le facteur XI et le facteur XIII, et dans une moindre mesure celle des composants du complexe prothrombinique.",
            "cite_spans": [],
            "section": "Sorbitol ::: Pasteurisation du plasma ::: Les techniques physiques ::: M\u00e9canisme d\u2019action des m\u00e9thodes d\u2019inactivation des agents pathog\u00e8nes dans les PSL",
            "ref_spans": []
        },
        {
            "text": "Il s\u2019agit d\u2019un sucre dont la pr\u00e9sence vise \u00e0 compl\u00e9ter le r\u00f4le du sorbitol dans le contr\u00f4le de l\u2019absence de formation d\u2019agr\u00e9gats et le maintien de l\u2019activit\u00e9 biologique des prot\u00e9ines plasmatiques. Dans le cas pr\u00e9sent, l\u2019ajout de saccharose pr\u00e9sente un int\u00e9r\u00eat sp\u00e9cifique dans le meilleur maintien de l\u2019activit\u00e9 coagulante des composants du complexe prothrombinique tels que le facteur IX et le facteur II (sup\u00e9rieur \u00e0 70 %).",
            "cite_spans": [],
            "section": "Saccharose ::: Pasteurisation du plasma ::: Les techniques physiques ::: M\u00e9canisme d\u2019action des m\u00e9thodes d\u2019inactivation des agents pathog\u00e8nes dans les PSL",
            "ref_spans": []
        },
        {
            "text": "Le calcium, \u00e0 une concentration de 1 \u00e0 10 mM, pr\u00e9sente un effet stabilisateur \u00e9tabli vis-\u00e0-vis de plusieurs facteurs de la coagulation, en premier lieu le facteur VIII.",
            "cite_spans": [],
            "section": "Gluconate de calcium ::: Pasteurisation du plasma ::: Les techniques physiques ::: M\u00e9canisme d\u2019action des m\u00e9thodes d\u2019inactivation des agents pathog\u00e8nes dans les PSL",
            "ref_spans": []
        },
        {
            "text": "Cet acide amin\u00e9 est ajout\u00e9 au plasma pr\u00e9alablement \u00e0 l\u2019\u00e9tape de pasteurisation car des exp\u00e9rimentations ont montr\u00e9 que sa pr\u00e9sence contribuait \u00e0 prot\u00e9ger le facteur VIII et le fibrinog\u00e8ne d\u2019une possible d\u00e9naturation, r\u00e9v\u00e9l\u00e9e par la perte de l\u2019activit\u00e9 coagulante et la diminution du pouvoir de coagulabilit\u00e9.",
            "cite_spans": [],
            "section": "Lysine ::: Pasteurisation du plasma ::: Les techniques physiques ::: M\u00e9canisme d\u2019action des m\u00e9thodes d\u2019inactivation des agents pathog\u00e8nes dans les PSL",
            "ref_spans": []
        },
        {
            "text": "Au m\u00eame titre que la lysine, l\u2019arginine est un acide amin\u00e9 dont la pr\u00e9sence joue un r\u00f4le favorable au maintien de l\u2019activit\u00e9 de facteurs de la coagulation dont le facteur IX, ou d\u2019anticoagulants comme la prot\u00e9ine C.",
            "cite_spans": [],
            "section": "Arginine ::: Pasteurisation du plasma ::: Les techniques physiques ::: M\u00e9canisme d\u2019action des m\u00e9thodes d\u2019inactivation des agents pathog\u00e8nes dans les PSL",
            "ref_spans": []
        },
        {
            "text": "\u00c0 l\u2019issue du palier de temp\u00e9rature (dix heures \u00e0 +60 \u00b0C), les stabilisants ajout\u00e9s sont \u00e9limin\u00e9s par une \u00e9tape de dialyse. La st\u00e9rilit\u00e9 bact\u00e9rienne du plasma pasteuris\u00e9 est assur\u00e9e par une filtration sur un filtre absolu de porosit\u00e9 de 0,22 \u03bcm (Tableau 1\n).",
            "cite_spans": [],
            "section": "Arginine ::: Pasteurisation du plasma ::: Les techniques physiques ::: M\u00e9canisme d\u2019action des m\u00e9thodes d\u2019inactivation des agents pathog\u00e8nes dans les PSL",
            "ref_spans": [
                {
                    "start": 245,
                    "end": 254,
                    "mention": "Tableau 1",
                    "ref_id": "TABREF0"
                }
            ]
        },
        {
            "text": "L\u2019amotosalen-HCl est une mol\u00e9cule de synth\u00e8se appartenant \u00e0 la famille des psoral\u00e8nes. Ce sont des compos\u00e9s actifs d\u2019origine v\u00e9g\u00e9tale qui sont depuis tr\u00e8s longtemps connus comme \u00e9tant des mol\u00e9cules photosensibles. Du fait de leur structure plane et de leur faible poids mol\u00e9culaire, la p\u00e9n\u00e9tration de ces mol\u00e9cules \u00e0 travers les membranes plasmiques est facilit\u00e9e. L\u2019amotosalen-HCl a pour propri\u00e9t\u00e9 de se fixer au niveau de la r\u00e9gion h\u00e9lico\u00efdale des acides nucl\u00e9iques doubles brins ou simple brin et s\u2019intercale entre les bases azot\u00e9es pyrimidiques. Une exposition au rayonnement de type UVA (320\u2013400 nm) d\u00e9clenche une r\u00e9action photochimique qui fixe par liaison covalente les mol\u00e9cules photo-activ\u00e9es aux bases pyrimidiques. Les doubles brins et les simples brins d\u2019acides nucl\u00e9iques sont ainsi fix\u00e9s entre eux par de multiples liaisons covalentes (une liaison toutes les 83 paires de bases). Les photo-produits de la r\u00e9action sont rapidement expuls\u00e9s de ces structures macromol\u00e9culaires. Une incubation prolong\u00e9e avec un compos\u00e9 adsorbant (quatre \u00e0 six heures) permet d\u2019\u00e9liminer l\u2019amotosalen HCI r\u00e9siduel ainsi que les photo-produits secondaires.",
            "cite_spans": [],
            "section": "Amotosalen-HCl\u00a0+\u00a0UVA (technique Intercept\u00ae de Cerus\u00a0[Pays-Bas])\u00a0: inactivation des concentr\u00e9s plaquettaires et du plasma ::: Les techniques photochimiques ::: M\u00e9canisme d\u2019action des m\u00e9thodes d\u2019inactivation des agents pathog\u00e8nes dans les PSL",
            "ref_spans": []
        },
        {
            "text": "L\u2019amotosalen-HCl se fixe \u00e9galement sur les lipides et les prot\u00e9ines. Ainsi, environ 15 % de l\u2019amotosalen-HCl initial se fixe sur les prot\u00e9ines plasmatiques et les plaquettes m\u00eame apr\u00e8s avoir effectu\u00e9 la r\u00e9duction de l\u2019amotosalen HCI et des photo-produits ; la majorit\u00e9 de l\u2019amotosalen HCI \u00e9tant li\u00e9e aux lipides et 1 \u00e0 2 % aux prot\u00e9ines.",
            "cite_spans": [],
            "section": "Amotosalen-HCl\u00a0+\u00a0UVA (technique Intercept\u00ae de Cerus\u00a0[Pays-Bas])\u00a0: inactivation des concentr\u00e9s plaquettaires et du plasma ::: Les techniques photochimiques ::: M\u00e9canisme d\u2019action des m\u00e9thodes d\u2019inactivation des agents pathog\u00e8nes dans les PSL",
            "ref_spans": []
        },
        {
            "text": "Du fait de l\u2019activation de l\u2019amotosalen-HCl par les rayonnements UVA, qui est absorb\u00e9 par l\u2019h\u00e9moglobine, cette technique ne peut pas s\u2019appliquer aux concentr\u00e9s de GR. Elle est efficace pour le plasma et les concentr\u00e9s plaquettaires (Tableau 2\n). Elle inactive un large spectre d\u2019agents pathog\u00e8nes tels que les virus envelopp\u00e9s et non envelopp\u00e9s, les bact\u00e9ries, les parasites et les leucocytes r\u00e9siduels. L\u2019inactivation des lymphocytes T est en effet sup\u00e9rieure \u00e0 5 log et la technique d\u00e9grade plus de paires de base (1/83) que l\u2019irradiation par rayonnement gamma (1/37 000).",
            "cite_spans": [],
            "section": "Amotosalen-HCl\u00a0+\u00a0UVA (technique Intercept\u00ae de Cerus\u00a0[Pays-Bas])\u00a0: inactivation des concentr\u00e9s plaquettaires et du plasma ::: Les techniques photochimiques ::: M\u00e9canisme d\u2019action des m\u00e9thodes d\u2019inactivation des agents pathog\u00e8nes dans les PSL",
            "ref_spans": [
                {
                    "start": 233,
                    "end": 242,
                    "mention": "Tableau 2",
                    "ref_id": "TABREF3"
                }
            ]
        },
        {
            "text": "La riboflavine est une mol\u00e9cule qui se fixe aux acides nucl\u00e9iques par intercalation. Un rayonnement ultraviolet g\u00e9n\u00e8re une photolyse du complexe macromol\u00e9culaire par transfert d\u2019\u00e9lectrons et r\u00e9action d\u2019oxydation de la guanine, une rupture des brins des acides nucl\u00e9iques et une formation de ponts covalents entre les acides nucl\u00e9iques ainsi d\u00e9grad\u00e9s. Le nombre de cassures des acides nucl\u00e9iques est de 1 pour 300 paires de base. Malgr\u00e9 cette photo-toxicit\u00e9 cibl\u00e9e sur les acides nucl\u00e9iques, la riboflavine est g\u00e9n\u00e9ralement reconnue non toxique. La riboflavine et ses photo-produits sont pr\u00e9sents dans une grande vari\u00e9t\u00e9 d\u2019aliments et la riboflavine, ses m\u00e9tabolites ainsi que ses photo-produits se retrouvent normalement dans le sang. Cependant, plusieurs \u00e9tudes doivent \u00eatre effectu\u00e9es car le niveau de photo-produits issus de la riboflavine est consid\u00e9rablement \u00e9lev\u00e9 dans les produits trait\u00e9s par cette technique. Elle est d\u00e9velopp\u00e9e pour inactiver le plasma et les concentr\u00e9s plaquettaires. Cette technique a d\u00e9montr\u00e9 son efficacit\u00e9 contre les agents pathog\u00e8nes tels que les virus, les parasites, les leucocytes et certains virus non envelopp\u00e9s (Tableau 3\n).",
            "cite_spans": [],
            "section": "Riboflavine (vitamine B2)\u00a0+\u00a0UV (technique Mirasol\u00ae de Caridian [\u00c9tats-Unis]) ::: Les techniques photochimiques ::: M\u00e9canisme d\u2019action des m\u00e9thodes d\u2019inactivation des agents pathog\u00e8nes dans les PSL",
            "ref_spans": [
                {
                    "start": 1150,
                    "end": 1159,
                    "mention": "Tableau 3",
                    "ref_id": "TABREF4"
                }
            ]
        },
        {
            "text": "Le colorant bleu de m\u00e9thyl\u00e8ne est une ph\u00e9nothiazine. Il pr\u00e9sente une affinit\u00e9 pour les acides nucl\u00e9iques (paires guanine\u2013cytosine). Apr\u00e8s absorption d\u2019\u00e9nergie lumineuse, une r\u00e9action photodynamique produit des formes d\u2019oxyg\u00e8ne actives entra\u00eenant la d\u00e9naturation irr\u00e9versible des acides nucl\u00e9iques et de certaines prot\u00e9ines. La r\u00e9plication et la transcription de l\u2019ADN et/ou ARN viral sont ainsi inhib\u00e9es. L\u2019enveloppe lipidique des virus envelopp\u00e9s poss\u00e8de une haute affinit\u00e9 pour le bleu de m\u00e9thyl\u00e8ne. Le colorant, localement concentr\u00e9, rend ces virus sensibles \u00e0 la photo-inactivation. Le colorant n\u2019\u00e9tant pas actif sur les pathog\u00e8nes intracellulaires, des strat\u00e9gies de lyse cellulaire (cong\u00e9lation\u2013d\u00e9cong\u00e9lation) ou de d\u00e9pl\u00e9tion cellulaire sont d\u00e9ploy\u00e9es. Il n\u2019est \u00e9galement pas actif sur les bact\u00e9ries (Tableau 4\n).",
            "cite_spans": [],
            "section": "Viro-att\u00e9nuation du plasma par le bleu de m\u00e9thyl\u00e8ne (technique Theraflex\u00ae de Macopharma [France]) ::: Les techniques photochimiques ::: M\u00e9canisme d\u2019action des m\u00e9thodes d\u2019inactivation des agents pathog\u00e8nes dans les PSL",
            "ref_spans": [
                {
                    "start": 807,
                    "end": 816,
                    "mention": "Tableau 4",
                    "ref_id": "TABREF5"
                }
            ]
        },
        {
            "text": "La m\u00e9thode d\u2019inactivation virale par solvant d\u00e9tergent (SD), utilis\u00e9e depuis 1985 pour le traitement des facteurs de l\u2019h\u00e9mostase a pu \u00eatre appliqu\u00e9e au plasma th\u00e9rapeutique, car elle s\u2019est av\u00e9r\u00e9e tr\u00e8s efficace dans l\u2019inactivation des virus envelopp\u00e9s. Depuis 1992, l\u2019unit\u00e9 de production de Bordeaux permet de fournir la France en PVA-SD.",
            "cite_spans": [],
            "section": "Plasma viro-att\u00e9nu\u00e9 par solvant-d\u00e9tergent (PVA-SD) ::: Technique biochimique ::: M\u00e9canisme d\u2019action des m\u00e9thodes d\u2019inactivation des agents pathog\u00e8nes dans les PSL",
            "ref_spans": []
        },
        {
            "text": "La d\u00e9monstration de la viro-att\u00e9nuation dans le PVA-SD est fond\u00e9e sur des \u00e9tudes de validation in vitro et des \u00e9tudes in vivo chez le chimpanz\u00e9. Les agents utilis\u00e9s pour la r\u00e9alisation de ces \u00e9tudes de validation sont des virus repr\u00e9sentatifs de la majorit\u00e9 des virus potentiellement impliqu\u00e9s, ou qui ont \u00e9t\u00e9 impliqu\u00e9s, dans les cas de transmissions virales transfusionnelles.",
            "cite_spans": [],
            "section": "Plasma viro-att\u00e9nu\u00e9 par solvant-d\u00e9tergent (PVA-SD) ::: Technique biochimique ::: M\u00e9canisme d\u2019action des m\u00e9thodes d\u2019inactivation des agents pathog\u00e8nes dans les PSL",
            "ref_spans": []
        },
        {
            "text": "Sur la base des \u00e9tudes de validation, le processus de production du PVA-SD :\u2022est consid\u00e9r\u00e9 comme tr\u00e8s efficace sur les virus envelopp\u00e9s potentiellement pr\u00e9sents dans le plasma et notamment efficace vis-\u00e0-vis du VIH 1/2, de l\u2019HTLV-I/II, des virus de l\u2019h\u00e9patite A, B et C ainsi que du CMV ;\u2022est sans action sur les virus nus. Cependant, des essais ont montr\u00e9 que certaines \u00e9tapes du processus (\u00e9limination des inactivateurs) induisent une \u00e9limination de certains agents infectieux. En outre, le m\u00e9lange des plasmas assure la pr\u00e9sence d\u2019anticorps dans le produit qui neutralisent certains virus, notamment des virus nus comme le virus de l\u2019h\u00e9patite A (VHA) et le parvovirus B19 ;\u2022\u00e9limine le risque de transmission du parvovirus B19, car la recherche des acides nucl\u00e9iques du Parvovirus B19 est effectu\u00e9e par le site de Bordeaux sur chaque plasma entrant dans la composition du pool ;\u2022\u00e9limine le risque de transmission du VHA, car la norme de la Pharmacop\u00e9e Europ\u00e9enne concernant le titre d\u2019anti-VHA neutralisant est constamment respect\u00e9e avec les plasmas pr\u00e9lev\u00e9s en France (\u2265 2000 mUI/mL) ;\u2022\u00e9limine les bact\u00e9ries puisque le processus de production inclue une filtration st\u00e9rilisante (Tableau 5\n).\n",
            "cite_spans": [],
            "section": "Plasma viro-att\u00e9nu\u00e9 par solvant-d\u00e9tergent (PVA-SD) ::: Technique biochimique ::: M\u00e9canisme d\u2019action des m\u00e9thodes d\u2019inactivation des agents pathog\u00e8nes dans les PSL",
            "ref_spans": [
                {
                    "start": 1182,
                    "end": 1191,
                    "mention": "Tableau 5",
                    "ref_id": "TABREF6"
                }
            ]
        },
        {
            "text": "La technique Intercept\u00ae a \u00e9t\u00e9 valid\u00e9e par l\u2019Afssaps pour les concentr\u00e9s plaquettaires d\u2019aph\u00e9r\u00e8se d\u00e9leucocyt\u00e9s (CPAD-IA) et les m\u00e9langes de concentr\u00e9s de plaquettes standards d\u00e9leucocyt\u00e9s (MCPSD-IA). Leurs caract\u00e9ristiques sont d\u00e9finies au Journal officiel. Actuellement, les concentr\u00e9s plaquettaires trait\u00e9s par amotosalen-HCl (CP-IA) sont pr\u00e9par\u00e9s par quatre EFS r\u00e9gionaux (Alsace, R\u00e9union, Guadeloupe-Guyane, Martinique). Les CP avant traitement ont un contenu plaquettaire compris entre 2 \u00d7 1011 et 7 \u00d7 1011 plaquettes. Celles-ci sont en suspension dans une solution additive (Intersol\u00ae) et le plasma r\u00e9siduel est compris entre 32 et 47 %, \u00e9vitant ainsi une fixation importante de l\u2019amotosalen-HCl sur les prot\u00e9ines plasmatiques. Les rayonnements UVA \u00e9tant absorb\u00e9s par l\u2019h\u00e9moglobine, la concentration en GR r\u00e9siduels dans le CP ne doit pas exc\u00e9der 4 \u00d7 106\n GR/mL afin de garantir une illumination efficace. Un dispositif m\u00e9dical \u00e0 usage unique (DMU) est connect\u00e9 aux CP et permet d\u2019effectuer les diff\u00e9rentes op\u00e9rations unitaires du proc\u00e9d\u00e9 Intercept\u00ae ; addition de l\u2019amotosalen-HCl, illumination, r\u00e9duction de l\u2019amotosalen r\u00e9siduel, conservation. L\u2019addition de 15 mL d\u2019amotosalen-HCl 3 mM (DMU petit volume) pour les CP de volume compris entre 255 et 325 mL ou de 17,5 mL d\u2019amotosalen HCl 3 mM (DMU grand volume) s\u2019effectue en transf\u00e9rant les CP dans la poche d\u2019illumination. La concentration en amotosalen varie ainsi entre 130 et 166 \u03bcM, la concentration efficace \u00e9tant comprise entre 120 et 180 \u03bcM. L\u2019op\u00e9ration d\u2019illumination s\u2019effectue sous agitation et permet de d\u00e9livrer par rayonnement UVA une dose \u00e9nerg\u00e9tique comprise entre 3,2 et 4,0 J/cm2 (DMU petit volume) ou entre 3,5 et 4,3 J/cm2 (DMU grand volume). Deux CP sont trait\u00e9s pour un cycle d\u2019illumination compris entre quatre et six minutes. L\u2019amotosalen r\u00e9siduel et les photo-produits sont ensuite \u00e9limin\u00e9s par adsorption au contact de billes adsorbantes immobilis\u00e9es dans une poche contenant le CP. Cette op\u00e9ration s\u2019effectue sous agitation et la dur\u00e9e minimale est de quatre heures (DMU petit volume) ou de six heures (DMU grand volume) avec une dur\u00e9e maximale limit\u00e9e \u00e0 16 heures. La concentration d\u2019amotosalen r\u00e9siduel doit \u00eatre inf\u00e9rieure ou \u00e9gale \u00e0 2 \u03bcM. Le CP issu de cette phase est conserv\u00e9 dans une poche de conservation pour plaquettes jusqu\u2019\u00e0 transfusion.",
            "cite_spans": [],
            "section": "Amotosalen-HCl\u00a0+\u00a0UVA (technique Intercept\u00ae) ::: Les concentr\u00e9s plaquettaires ::: Applications et proc\u00e9d\u00e9s",
            "ref_spans": []
        },
        {
            "text": "Les \u00e9tudes de validation sont en cours pour les CP trait\u00e9s par la technique Mirasol. Cette technique exige des CP dont les plaquettes sont en suspension dans 100 % de plasma. Le CP est transf\u00e9r\u00e9 par connexion st\u00e9rile dans la poche d\u2019illumination. L\u2019addition de la solution de riboflavine s\u2019effectue par transfert de celle-ci dans la poche d\u2019illumination. La concentration de la riboflavine est alors approximativement de 50 \u03bcM. L\u2019illumination par rayonnement UV (285 \u00e0 365 nm) permet de d\u00e9livrer au CP une dose \u00e9nerg\u00e9tique de 6,2 J/mL [31]. Le temps d\u2019exposition au rayonnement est d\u00e9pendant du volume du CP qui doit \u00eatre compris entre 170 et 360 mL et est de l\u2019ordre de 10 minutes. Un CP est illumin\u00e9 par cycle d\u2019illumination. Il est ensuite conserv\u00e9 dans la poche jusqu\u2019\u00e0 transfusion.",
            "cite_spans": [
                {
                    "start": 535,
                    "end": 539,
                    "mention": "[31]",
                    "ref_id": "BIBREF24"
                }
            ],
            "section": "Riboflavine\u00a0+\u00a0UV (technique Mirasol\u00ae) ::: Les concentr\u00e9s plaquettaires ::: Applications et proc\u00e9d\u00e9s",
            "ref_spans": []
        },
        {
            "text": "Bien que non disponible en France et encore \u00e0 l\u2019\u00e9tude, un proc\u00e9d\u00e9 de r\u00e9duction des pathog\u00e8nes par action d\u2019un rayonnement UVC est d\u00e9crit [17]. Les m\u00e9langes de concentr\u00e9s de plaquettes \u00e0 traiter par cette technique sont suspendus en solution additive (35 % plasma, 65 % solution cristallo\u00efde de conservation). Le m\u00e9lange de concentr\u00e9s de plaquettes d\u00e9leucocyt\u00e9s est ensuite transf\u00e9r\u00e9 dans une poche perm\u00e9able aux rayonnements UV. La poche est illumin\u00e9e (254 nm) \u00e0 une dose de 0,4 J/cm2 pendant 60 secondes et constamment et vigoureusement agit\u00e9e (agitation orbitale). Apr\u00e8s illumination, le produit est transf\u00e9r\u00e9 dans une poche permettant la conservation du m\u00e9lange de concentr\u00e9s de plaquettes.",
            "cite_spans": [
                {
                    "start": 137,
                    "end": 141,
                    "mention": "[17]",
                    "ref_id": "BIBREF8"
                }
            ],
            "section": "UVC ::: Les concentr\u00e9s plaquettaires ::: Applications et proc\u00e9d\u00e9s",
            "ref_spans": []
        },
        {
            "text": "Le PVA-SD est pr\u00e9par\u00e9 en France (EFS-Aquitaine-Limousin) \u00e0 partir d\u2019un pool de plasma de 100 donneurs maximum (contre 400 dans le reste de l\u2019Europe). Il s\u2019agit de pools de plasmas d\u2019aph\u00e9r\u00e8se de m\u00eame groupe sanguin congel\u00e9s dans les six heures suivant le pr\u00e9l\u00e8vement.",
            "cite_spans": [],
            "section": "Pr\u00e9paration du plasma frais congel\u00e9 viro-att\u00e9nu\u00e9 par solvant-d\u00e9tergent d\u00e9leucocyt\u00e9 ::: Le plasma ::: Applications et proc\u00e9d\u00e9s",
            "ref_spans": []
        },
        {
            "text": "L\u2019inactivation des agents pathog\u00e8nes est r\u00e9alis\u00e9e apr\u00e8s cong\u00e9lation\u2013d\u00e9cong\u00e9lation (qui d\u00e9truit les cellules) en utilisant un solvant (tri n-butyl phosphate : TnBP) et un d\u00e9tergent (Triton X100). Cette technique n\u00e9cessite plusieurs filtrations qui entra\u00eenent une \u00e9limination totale des cellules (et des pathog\u00e8nes intracellulaires), des d\u00e9bris cellulaires, des antig\u00e8nes (plaquettaires, \u00e9rythrocytaires, leucocytaires) et des bact\u00e9ries. L\u2019\u00e9limination des inactivateurs s\u2019op\u00e8re par addition d\u2019huile de ricin suivie d\u2019une chromatographie. Afin de r\u00e9pondre \u00e0 la norme des caract\u00e9ristiques des PSL (FVIIIc > 0,7 UI/mL), les plasmas de groupe O sont concentr\u00e9s par ultrafiltration. Apr\u00e8s filtration st\u00e9rilisante, le plasma, produit acellulaire et st\u00e9rile (chaque lot de fabrication un contr\u00f4le de st\u00e9rilit\u00e9 et d\u2019apyrog\u00e9nicit\u00e9), est r\u00e9parti aseptiquement en unit\u00e9s de 200 mL.",
            "cite_spans": [],
            "section": "Pr\u00e9paration du plasma frais congel\u00e9 viro-att\u00e9nu\u00e9 par solvant-d\u00e9tergent d\u00e9leucocyt\u00e9 ::: Le plasma ::: Applications et proc\u00e9d\u00e9s",
            "ref_spans": []
        },
        {
            "text": "Le plasma viro-att\u00e9nu\u00e9 par le bleu de m\u00e9thyl\u00e8ne est produit par huit laboratoires de pr\u00e9paration des PSL en France. Il est depuis septembre 2008 l\u2019un des trois produits plasmatiques th\u00e9rapeutiques d\u00e9livr\u00e9 par l\u2019EFS vers les \u00e9tablissements de soins.",
            "cite_spans": [],
            "section": "Pr\u00e9paration du plasma viro-att\u00e9nu\u00e9 par le bleu de m\u00e9thyl\u00e8ne ::: Le plasma ::: Applications et proc\u00e9d\u00e9s",
            "ref_spans": []
        },
        {
            "text": "La pr\u00e9paration du plasma viro-att\u00e9nu\u00e9 est r\u00e9alis\u00e9e suivant un protocole standardis\u00e9 combinant :\u2022l\u2019utilisation d\u2019un plasma d\u2019aph\u00e9r\u00e8se d\u00e9leucocyt\u00e9 (moins de 104 leucocytes r\u00e9siduels par litre) ;\u2022la mise en \u0153uvre d\u2019un dispositif \u00e0 usage unique permettant apr\u00e8s connexion st\u00e9rile \u00e0 la poche de plasma d\u2019additionner 85 \u03bcg de bleu de m\u00e9thyl\u00e8ne permettant d\u2019obtenir une concentration moyenne finale en bleu de m\u00e9thyl\u00e8ne de 0,84 \u00e0 1,13 \u03bcM dans le plasma ;\u2022l\u2019apport de l\u2019\u00e9nergie lumineuse n\u00e9cessaire \u00e0 l\u2019illumination par une source \u00e9mettant \u00e0 590 nm et d\u00e9livrant une dose de 180 J/cm2. Quatre poches sont trait\u00e9es par cycle pendant 20 \u00e0 25 minutes ;\u2022la filtration du plasma trait\u00e9 pour l\u2019\u00e9limination du bleu de m\u00e9thyl\u00e8ne et de ses r\u00e9sidus photochimiques en vue d\u2019obtenir une concentration en bleu de m\u00e9thyl\u00e8ne r\u00e9siduel inf\u00e9rieure \u00e0 30 \u03bcg/L. Le volume du plasma doit \u00eatre compris entre 200 et 300 mL ;\u2022la cong\u00e9lation du produit viro-att\u00e9nu\u00e9 qui doit intervenir dans les 12 heures apr\u00e8s le pr\u00e9l\u00e8vement.\n",
            "cite_spans": [],
            "section": "Pr\u00e9paration du plasma viro-att\u00e9nu\u00e9 par le bleu de m\u00e9thyl\u00e8ne ::: Le plasma ::: Applications et proc\u00e9d\u00e9s",
            "ref_spans": []
        },
        {
            "text": "La technique Intercept\u00ae a \u00e9t\u00e9 valid\u00e9e par l\u2019Afssaps pour le plasma pr\u00e9lev\u00e9 par aph\u00e9r\u00e8se (plasma frais congel\u00e9 d\u2019aph\u00e9r\u00e8se d\u00e9leucocyt\u00e9 trait\u00e9 pour att\u00e9nuation d\u2019agent pathog\u00e8ne par Amotosalen [PFCAD-IA]). Ses caract\u00e9ristiques sont d\u00e9finies au Journal officiel. Actuellement, le PFCAD-IA est pr\u00e9par\u00e9 par l\u2019EFS-Alsace. Le volume de plasma avant traitement doit \u00eatre compris entre 385 et 650 mL. La concentration en GR r\u00e9siduels ne doit pas exc\u00e9der 4 \u00d7 106\n GR/mL. Un DMU est connect\u00e9 au plasma et permet d\u2019effectuer les diff\u00e9rentes op\u00e9rations unitaires du proc\u00e9d\u00e9 Intercept ; addition de l\u2019amotosalen, illumination, r\u00e9duction de l\u2019amotosalen r\u00e9siduel, conservation. L\u2019addition de 15 mL d\u2019amotosalen-HCl 6 mM s\u2019effectue en transf\u00e9rant le plasma dans la poche d\u2019illumination. La concentration en amotosalen varie ainsi entre 135 et 225 \u03bcM. L\u2019op\u00e9ration d\u2018illumination s\u2019effectue sous agitation et permet de d\u00e9livrer par rayonnement UVA une dose \u00e9nerg\u00e9tique comprise entre 5,8 et 7,0 J/cm2. Deux plasmas de 650 mL maximum sont trait\u00e9s pour un cycle d\u2019illumination compris entre six et huit minutes. L\u2019amotosalen r\u00e9siduel est ensuite \u00e9limin\u00e9 par adsorption au contact de billes adsorbantes immobilis\u00e9es dans un filtre. Cette op\u00e9ration s\u2019effectue par transfert du plasma illumin\u00e9 de la poche d\u2019illumination vers les trois poches de conservation. La dur\u00e9e moyenne est inf\u00e9rieure \u00e0 30 minutes. La concentration d\u2019amotosalen r\u00e9siduel doit \u00eatre inf\u00e9rieure ou \u00e9gale \u00e0 2 \u03bcM. Le plasma est ensuite r\u00e9parti par gravit\u00e9 entre les trois poches pour constituer trois unit\u00e9s th\u00e9rapeutiques d\u2019un volume sup\u00e9rieur \u00e0 200 mL. La cong\u00e9lation de ces unit\u00e9s doit se faire dans les huit heures suivant l\u2019heure de fin de pr\u00e9l\u00e8vement.",
            "cite_spans": [],
            "section": "Pr\u00e9paration du plasma frais congel\u00e9 viro-att\u00e9nu\u00e9 par amotosalen ::: Le plasma ::: Applications et proc\u00e9d\u00e9s",
            "ref_spans": []
        },
        {
            "text": "La fabrication d\u2019un lot de plasma pasteuris\u00e9 met en \u0153uvre un volume de 100 dons (ou moins) obtenus par plasmaph\u00e9r\u00e8se. En tant que mat\u00e9riel de d\u00e9part, les plasmaph\u00e9r\u00e8ses se pr\u00e9sentent sous forme congel\u00e9e, la teneur en facteur VIII moyenne doit \u00eatre \u00e9gale ou sup\u00e9rieure \u00e0 0,7 UI/mL. Apr\u00e8s d\u00e9cong\u00e9lation, au lot de plasma, sont additionn\u00e9s diff\u00e9rents stabilisants ; la quantit\u00e9 de chacun d\u2019eux est proportionnelle au volume de plasma mis en jeu. Apr\u00e8s homog\u00e9n\u00e9isation, le m\u00e9lange est port\u00e9 \u00e0 une temp\u00e9rature de +60 \u00b0C pendant une dur\u00e9e de dix heures. En fin de pasteurisation, une \u00e9tape de dialyse contre un tampon formul\u00e9 en acides amin\u00e9s assure l\u2019\u00e9limination des sucres \u00ab thermo-protecteurs \u00bb. Cette dialyse est assur\u00e9e par l\u2019utilisation de membranes d\u2019ultra-filtration de 10 KD. En fin de process, la teneur en prot\u00e9ines du plasma est ajust\u00e9e au regard des caract\u00e9ristiques vis\u00e9es. Avant d\u2019\u00eatre r\u00e9parti aseptiquement en unit\u00e9s de 200 mL puis congel\u00e9, le lot de plasma ajust\u00e9 subit une filtration st\u00e9rilisante sur un filtre absolu de 0,22 \u03bcm. R\u00e9v\u00e9l\u00e9e par une approche prot\u00e9omique, la pasteurisation a la particularit\u00e9 d\u2019\u00eatre tr\u00e8s peu d\u00e9naturante au regard de l\u2019ensemble des prot\u00e9ines plasmatiques.",
            "cite_spans": [],
            "section": "Pasteurisation ::: Le plasma ::: Applications et proc\u00e9d\u00e9s",
            "ref_spans": []
        },
        {
            "text": "Le volume d\u2019une poche de PVA-SD est de 200 mL. La concentration minimale en facteur VIII est 0,7 UI/mL. Les concentrations r\u00e9siduelles en TnBP et en Triton X 100 sont respectivement inf\u00e9rieures \u00e0 2 \u03bcg/mL et \u00e0 5 \u03bcg/mL. Le m\u00e9lange permet une standardisation des taux des principes actifs contenus dans le produit final, et des contr\u00f4les sont effectu\u00e9s sur chaque lot pour v\u00e9rifier l\u2019innocuit\u00e9 et l\u2019efficacit\u00e9 du produit (Tableau 6\n). Les essais de validation ont montr\u00e9 que le traitement SD n\u2019alt\u00e8re ni les tests de coagulation, ni les principales prot\u00e9ines de la coagulation, mais entra\u00eene une diminution de l\u2019alpha 2 anti-plasmine. Le PVA-SD ne contient pas les multim\u00e8res de tr\u00e8s haut poids mol\u00e9culaire de facteur Willebrand. L\u2019activit\u00e9 fonctionnelle de la prot\u00e9ine ADAMTS 13 est maintenue. Une recherche d\u2019anticorps anti-HLA et anti-leucocytaire est syst\u00e9matiquement effectu\u00e9e sur tous les lots.",
            "cite_spans": [],
            "section": "Plasma solvant-d\u00e9tergent ::: Donn\u00e9es et contr\u00f4le qualit\u00e9",
            "ref_spans": [
                {
                    "start": 419,
                    "end": 428,
                    "mention": "Tableau 6",
                    "ref_id": "TABREF7"
                }
            ]
        },
        {
            "text": "La composition finale du plasma viro-att\u00e9nu\u00e9 par le bleu de m\u00e9thyl\u00e8ne est d\u00e9crite par plusieurs \u00e9tudes (Tableau 7\n).",
            "cite_spans": [],
            "section": "Plasma bleu de m\u00e9thyl\u00e8ne (PVABM) ::: Donn\u00e9es et contr\u00f4le qualit\u00e9",
            "ref_spans": [
                {
                    "start": 104,
                    "end": 113,
                    "mention": "Tableau 7",
                    "ref_id": "TABREF8"
                }
            ]
        },
        {
            "text": "La viro-att\u00e9nuation du plasma par le bleu de m\u00e9thyl\u00e8ne impacte les facteurs de coagulation. Une r\u00e9duction de l\u2019ordre de 24 \u00e0 39 % du fibrinog\u00e8ne [49] est publi\u00e9e, de 4 \u00e0 32 % du facteur V, de 13 \u00e0 33 % du facteur VIII, de 11 \u00e0 23 % du facteur IX et de 17 \u00e0 27 % du facteur XI [50]. En France, les contr\u00f4les de qualit\u00e9 r\u00e9alis\u00e9s sur les six premiers mois de fabrication du PVABM montrent que la technique mise en \u0153uvre permet d\u2019obtenir des plasmas conformes aux caract\u00e9ristiques des PSL.",
            "cite_spans": [
                {
                    "start": 145,
                    "end": 149,
                    "mention": "[49]",
                    "ref_id": "BIBREF43"
                },
                {
                    "start": 276,
                    "end": 280,
                    "mention": "[50]",
                    "ref_id": "BIBREF45"
                }
            ],
            "section": "Plasma bleu de m\u00e9thyl\u00e8ne (PVABM) ::: Donn\u00e9es et contr\u00f4le qualit\u00e9",
            "ref_spans": []
        },
        {
            "text": "Les r\u00e9sultats des param\u00e8tres plasmatiques pour le plasma amotosalen sont pr\u00e9sent\u00e9s dans le Tableau 8\n.",
            "cite_spans": [],
            "section": "Plasma amotosalen ::: Donn\u00e9es et contr\u00f4le qualit\u00e9",
            "ref_spans": [
                {
                    "start": 91,
                    "end": 100,
                    "mention": "Tableau 8",
                    "ref_id": "TABREF9"
                }
            ]
        },
        {
            "text": "\u00c0 la demande de l\u2019Afssaps, une \u00e9tude de stabilit\u00e9 portant sur 50 lots pour une p\u00e9riode de 24 mois a \u00e9t\u00e9 r\u00e9alis\u00e9e (Tableau 9\n).",
            "cite_spans": [],
            "section": "Plasma pasteuris\u00e9 ::: Donn\u00e9es et contr\u00f4le qualit\u00e9",
            "ref_spans": [
                {
                    "start": 114,
                    "end": 123,
                    "mention": "Tableau 9",
                    "ref_id": "TABREF10"
                }
            ]
        },
        {
            "text": "En termes de volume, le rendement de la technique (volume plasma viro inactiv\u00e9/volume plasma initial) est proche de 100 %.",
            "cite_spans": [],
            "section": "Plasma pasteuris\u00e9 ::: Donn\u00e9es et contr\u00f4le qualit\u00e9",
            "ref_spans": []
        },
        {
            "text": "Les r\u00e9sultats des param\u00e8tres des plaquettes trait\u00e9es par riboflavine et UV sont pr\u00e9sent\u00e9s dans le Tableau 10\n.",
            "cite_spans": [],
            "section": "Concentr\u00e9s plaquettaires trait\u00e9s par riboflavine et UV ::: Donn\u00e9es et contr\u00f4le qualit\u00e9",
            "ref_spans": [
                {
                    "start": 98,
                    "end": 108,
                    "mention": "Tableau 10",
                    "ref_id": "TABREF1"
                }
            ]
        },
        {
            "text": "Les r\u00e9sultats des param\u00e8tres des plaquettes trait\u00e9es par amotosalen et UVA sont pr\u00e9sent\u00e9s dans le Tableau 11\n.",
            "cite_spans": [],
            "section": "Concentr\u00e9s plaquettaires trait\u00e9s par amotosalen et UVA ::: Donn\u00e9es et contr\u00f4le qualit\u00e9",
            "ref_spans": [
                {
                    "start": 98,
                    "end": 108,
                    "mention": "Tableau 11",
                    "ref_id": "TABREF2"
                }
            ]
        },
        {
            "text": "De la transfusion du sang total au principe de transfusion s\u00e9lective sont n\u00e9s les laboratoires de pr\u00e9paration des PSL. L\u2019activit\u00e9 principale de ces unit\u00e9s a \u00e9t\u00e9 pendant de nombreuses ann\u00e9es limit\u00e9e \u00e0 la s\u00e9paration et \u00e0 la conservation des produits sanguins. La recherche ax\u00e9e sur l\u2019obtention d\u2019un produit sanguin labile de haute qualit\u00e9 ayant comme objectif l\u2019augmentation de la s\u00e9curit\u00e9 transfusionnelle a fait progresser les techniques et les technologies disponibles pour les laboratoires de pr\u00e9paration. Des m\u00e9thodes d\u2019att\u00e9nuation des pathog\u00e8nes sont actuellement valid\u00e9es, disponibles et mises en \u0153uvre en France. Elles sont aujourd\u2019hui essentiellement appliqu\u00e9es aux produits plasmatiques bien que disponibles et autoris\u00e9es pour les produits plaquettaires. Des \u00e9tudes r\u00e9centes, permettent d\u2019esp\u00e9rer l\u2019introduction de concentr\u00e9s globulaires trait\u00e9s pour att\u00e9nuation des agents pathog\u00e8nes en th\u00e9rapeutique dans les prochaines ann\u00e9es. L\u2019\u00e9volution des techniques et la mise en place de celles-ci dans nos plateaux techniques devraient permettre \u00e0 terme d\u2019apporter \u00e0 tous les patients des produits de haute s\u00e9curit\u00e9, poss\u00e9dant une activit\u00e9 optimale et d\u00e9nu\u00e9e de risques infectieux majeurs.",
            "cite_spans": [],
            "section": "Conclusion",
            "ref_spans": []
        },
        {
            "text": "Les auteurs n\u2019ont pas d\u00e9clar\u00e9 de conflits d\u2019int\u00e9r\u00eats.",
            "cite_spans": [],
            "section": "Conflits d\u2019int\u00e9r\u00eats",
            "ref_spans": []
        }
    ],
    "ref_entries": {
        "TABREF0": {
            "text": "Tableau 1: Efficacit\u00e9 du proc\u00e9d\u00e9 de pasteurisation du plasma sur les agents pathog\u00e8nes.\n",
            "type": "table"
        },
        "TABREF1": {
            "text": "Tableau 10: R\u00e9sultats des param\u00e8tres des plaquettes trait\u00e9es par riboflavine et UV dans les \u00e9tudes publi\u00e9es [30], [31].\n",
            "type": "table"
        },
        "TABREF2": {
            "text": "Tableau 11: R\u00e9sultats des param\u00e8tres des plaquettes trait\u00e9es par amotosalen et UVA dans les \u00e9tudes publi\u00e9es [52], [53], [54], [55], [56].\n",
            "type": "table"
        },
        "TABREF3": {
            "text": "Tableau 2: Efficacit\u00e9 du traitement par l\u2019amotosalen HCI et les UVA sur les agents pathog\u00e8nes [19], [20], [21], [22], [23], [24], [25], [26], [27], [28].\n",
            "type": "table"
        },
        "TABREF4": {
            "text": "Tableau 3: Efficacit\u00e9 du traitement par la riboflavine et les UV sur les agents pathog\u00e8nes dans les \u00e9tudes publi\u00e9es [29], [30], [31], [32], [33], [34].\n",
            "type": "table"
        },
        "TABREF5": {
            "text": "Tableau 4: Efficacit\u00e9 du traitement par le bleu de m\u00e9thyl\u00e8ne sur les virus dans l\u2019\u00e9tude publi\u00e9e [35].\n",
            "type": "table"
        },
        "TABREF6": {
            "text": "Tableau 5: Efficacit\u00e9 du proc\u00e9d\u00e9 solvant-d\u00e9tergent sur les virus.\n",
            "type": "table"
        },
        "TABREF7": {
            "text": "Tableau 6: Principes actifs : h\u00e9mostase.\n",
            "type": "table"
        },
        "TABREF8": {
            "text": "Tableau 7: R\u00e9sultats des param\u00e8tres plasmatiques pour le plasma bleu de m\u00e9thyl\u00e8ne dans les \u00e9tudes publi\u00e9es [35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46], [47], [48].\n",
            "type": "table"
        },
        "TABREF9": {
            "text": "Tableau 8: R\u00e9sultats des param\u00e8tres plasmatiques pour le plasma amotosalen dans l\u2019\u00e9tude publi\u00e9e [51].\n",
            "type": "table"
        },
        "TABREF10": {
            "text": "Tableau 9: R\u00e9sultats des param\u00e8tres plasmatiques pour le plasma pasteuris\u00e9.\n",
            "type": "table"
        }
    },
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "Proceedings of a Consensus Conference\u00a0: pathogen inactivation-making decisions about new technologies",
            "authors": [
                {
                    "first": "K.E.",
                    "middle": [],
                    "last": "Webert",
                    "suffix": ""
                },
                {
                    "first": "C.M.",
                    "middle": [],
                    "last": "Cserti",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Hannon",
                    "suffix": ""
                },
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Lin",
                    "suffix": ""
                },
                {
                    "first": "K.",
                    "middle": [],
                    "last": "Pavenski",
                    "suffix": ""
                },
                {
                    "first": "J.M.",
                    "middle": [],
                    "last": "Pendergrast",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Transfus Med Rev",
            "volume": "22",
            "issn": "",
            "pages": "1-34",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "Prevention of transfusion associated cytomegalovirus infection in very low-birthweight infants using frozen blood and donors sero-negative for cytomegalovirus",
            "authors": [
                {
                    "first": "S.P.",
                    "middle": [],
                    "last": "Adler",
                    "suffix": ""
                },
                {
                    "first": "L.T.",
                    "middle": [],
                    "last": "Lawrence",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Bagget",
                    "suffix": ""
                },
                {
                    "first": "V.",
                    "middle": [],
                    "last": "Biro",
                    "suffix": ""
                },
                {
                    "first": "D.E.",
                    "middle": [],
                    "last": "Sharp",
                    "suffix": ""
                }
            ],
            "year": 1984,
            "venue": "Transfusion",
            "volume": "24",
            "issn": "",
            "pages": "333-335",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF2": {
            "title": "Infections \u00e0 cytom\u00e9galovirus post-transfusionnelles\u00a0: incidence et moyens de pr\u00e9vention",
            "authors": [
                {
                    "first": "G.",
                    "middle": [],
                    "last": "Andreu",
                    "suffix": ""
                },
                {
                    "first": "A.M.",
                    "middle": [],
                    "last": "Marini\u00e8re",
                    "suffix": ""
                },
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Fretz",
                    "suffix": ""
                },
                {
                    "first": "J.F.",
                    "middle": [],
                    "last": "Emile",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "le groupe CMV de la SNTS",
                    "suffix": ""
                },
                {
                    "first": "P.",
                    "middle": [],
                    "last": "Bierling",
                    "suffix": ""
                }
            ],
            "year": 1991,
            "venue": "Rev Fr Transfus Hemobiol",
            "volume": "34",
            "issn": "",
            "pages": "213-232",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF3": {
            "title": "A comparison of filtered leukocyte reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion associated CMV infection after marrow transplant",
            "authors": [
                {
                    "first": "R.A.",
                    "middle": [],
                    "last": "Bowden",
                    "suffix": ""
                },
                {
                    "first": "S.J.",
                    "middle": [],
                    "last": "Slichter",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Sayers",
                    "suffix": ""
                },
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Weisdorf",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Cays",
                    "suffix": ""
                },
                {
                    "first": "G.",
                    "middle": [],
                    "last": "Schoch",
                    "suffix": ""
                }
            ],
            "year": 1995,
            "venue": "Blood",
            "volume": "86",
            "issn": "",
            "pages": "3598-3603",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF4": {
            "title": "",
            "authors": [
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Kobayashi",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "K.W.",
                    "middle": [],
                    "last": "Won",
                    "suffix": ""
                },
                {
                    "first": "T.A.",
                    "middle": [],
                    "last": "Takahashi",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Ikeda",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Sekiguchi",
                    "suffix": ""
                }
            ],
            "year": 1993,
            "venue": "Clinical application of leukocyte depletion",
            "volume": "",
            "issn": "",
            "pages": "138-148",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF5": {
            "title": "Efficacy of Epstein-Barr virus removal by leukoreduction of red blood cells",
            "authors": [
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Qu",
                    "suffix": ""
                },
                {
                    "first": "S.S.",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "D.T.",
                    "middle": [],
                    "last": "Rowe",
                    "suffix": ""
                },
                {
                    "first": "D.J.",
                    "middle": [],
                    "last": "Triulzi",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Transfusion",
            "volume": "45",
            "issn": "",
            "pages": "591-595",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF6": {
            "title": "Effect of gamma irradiation on the human immunodeficiency virus and human coagulation proteins",
            "authors": [
                {
                    "first": "A.D.",
                    "middle": [],
                    "last": "Kitchen",
                    "suffix": ""
                },
                {
                    "first": "G.F.",
                    "middle": [],
                    "last": "Mann",
                    "suffix": ""
                },
                {
                    "first": "J.F.",
                    "middle": [],
                    "last": "Harrison",
                    "suffix": ""
                },
                {
                    "first": "A.J.",
                    "middle": [],
                    "last": "Zuckerman",
                    "suffix": ""
                }
            ],
            "year": 1989,
            "venue": "Vox Sang",
            "volume": "56",
            "issn": "",
            "pages": "223-229",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF7": {
            "title": "Use of laser-UV for inactivation of virus in blood products",
            "authors": [
                {
                    "first": "K.N.",
                    "middle": [],
                    "last": "Prodouz",
                    "suffix": ""
                },
                {
                    "first": "J.C.",
                    "middle": [],
                    "last": "Fratantoni",
                    "suffix": ""
                },
                {
                    "first": "E.J.",
                    "middle": [],
                    "last": "Boone",
                    "suffix": ""
                },
                {
                    "first": "R.F.",
                    "middle": [],
                    "last": "Bonner",
                    "suffix": ""
                }
            ],
            "year": 1987,
            "venue": "Blood",
            "volume": "70",
            "issn": "",
            "pages": "589-592",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF8": {
            "title": "",
            "authors": [
                {
                    "first": "F.",
                    "middle": [],
                    "last": "Tolksdorf",
                    "suffix": ""
                },
                {
                    "first": "W.H.",
                    "middle": [],
                    "last": "Walker",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Mohr",
                    "suffix": ""
                },
                {
                    "first": "U.",
                    "middle": [],
                    "last": "Gravemann",
                    "suffix": ""
                },
                {
                    "first": "T.H.",
                    "middle": [],
                    "last": "Mueller",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "AABB Annual Meeting",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF9": {
            "title": "Potential and limitation of UVC irradiation for the inactivation of pathogens in platelet concentrates",
            "authors": [
                {
                    "first": "G.",
                    "middle": [],
                    "last": "Terpstra Fokke",
                    "suffix": ""
                },
                {
                    "first": "A.B.",
                    "middle": [],
                    "last": "Van\u2019t Wout",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Schuitemaker",
                    "suffix": ""
                },
                {
                    "first": "F.",
                    "middle": [],
                    "last": "Van Engelenburg",
                    "suffix": ""
                },
                {
                    "first": "D.W.C.",
                    "middle": [],
                    "last": "Dekkers",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Verhaar",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Transfusion",
            "volume": "48",
            "issn": "",
            "pages": "304-313",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF10": {
            "title": "Photochemical treatment of platelet concentrates with Amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria",
            "authors": [
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Lin",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Dikeman",
                    "suffix": ""
                },
                {
                    "first": "B.",
                    "middle": [],
                    "last": "Molini",
                    "suffix": ""
                },
                {
                    "first": "S.A.",
                    "middle": [],
                    "last": "Lukehart",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Lane",
                    "suffix": ""
                },
                {
                    "first": "K.",
                    "middle": [],
                    "last": "Dupuis",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Transfusion",
            "volume": "44",
            "issn": "",
            "pages": "1496-1504",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF11": {
            "title": "Pathogen inactivation: a new paradigm for blood safety",
            "authors": [
                {
                    "first": "J.",
                    "middle": [],
                    "last": "McCullough",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Transfusion",
            "volume": "47",
            "issn": "",
            "pages": "2180-2184",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF12": {
            "title": "Inactivation of viruses in platelet concentrates by photochemical treatment with Amotosalen and long-wavelength ultraviolet light",
            "authors": [
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Lin",
                    "suffix": ""
                },
                {
                    "first": "C.V.",
                    "middle": [],
                    "last": "Hanson",
                    "suffix": ""
                },
                {
                    "first": "H.J.",
                    "middle": [],
                    "last": "Alter",
                    "suffix": ""
                },
                {
                    "first": "V.",
                    "middle": [],
                    "last": "Jauvin",
                    "suffix": ""
                },
                {
                    "first": "K.A.",
                    "middle": [],
                    "last": "Bernard",
                    "suffix": ""
                },
                {
                    "first": "K.K.",
                    "middle": [],
                    "last": "Murthy",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Transfusion",
            "volume": "45",
            "issn": "",
            "pages": "580-590",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF13": {
            "title": "Amotosalen photochemical inactivation of severe acute respiratory syndrome coronavirus in human platelet concentrates",
            "authors": [
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Pinna",
                    "suffix": ""
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Sampson-Johannes",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Clementi",
                    "suffix": ""
                },
                {
                    "first": "G.",
                    "middle": [],
                    "last": "Poli",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Rossini",
                    "suffix": ""
                },
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Lin",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Transfus Med",
            "volume": "15",
            "issn": "",
            "pages": "269-276",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF14": {
            "title": "Leishmania inactivation in human pheresis platelets by a psoralen (Amotosalen HCl) and long-wavelength ultraviolet irradiation",
            "authors": [
                {
                    "first": "R.T.",
                    "middle": [],
                    "last": "Eastman",
                    "suffix": ""
                },
                {
                    "first": "L.K.",
                    "middle": [],
                    "last": "Barrett",
                    "suffix": ""
                },
                {
                    "first": "K.",
                    "middle": [],
                    "last": "Dupuis",
                    "suffix": ""
                },
                {
                    "first": "F.S.",
                    "middle": [],
                    "last": "Buckner",
                    "suffix": ""
                },
                {
                    "first": "W.C.",
                    "middle": [],
                    "last": "Van Voorhis",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Transfusion",
            "volume": "45",
            "issn": "",
            "pages": "1459-1463",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF15": {
            "title": "Trypanosoma cruzi Inactivation in Human Platelet Concentrates and Plasma by a Psoralen (Amotosalen HCl) and Long-Wavelength UV",
            "authors": [
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Wesley",
                    "suffix": ""
                },
                {
                    "first": "",
                    "middle": [],
                    "last": "Van Voorhis",
                    "suffix": ""
                },
                {
                    "first": "Lynn",
                    "middle": [
                        "K."
                    ],
                    "last": "Barrett",
                    "suffix": ""
                },
                {
                    "first": "Richard",
                    "middle": [
                        "T."
                    ],
                    "last": "Eastman",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Antimicrob Agents Chemother",
            "volume": "47",
            "issn": "",
            "pages": "475-479",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF16": {
            "title": "Photochemical treatment of plasma with Amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function",
            "authors": [
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Singh",
                    "suffix": ""
                },
                {
                    "first": "L.S.",
                    "middle": [],
                    "last": "Sawyer",
                    "suffix": ""
                },
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Pinkoski",
                    "suffix": ""
                },
                {
                    "first": "K.W.",
                    "middle": [],
                    "last": "Dupuis",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Hsu",
                    "suffix": ""
                },
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Lin",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Transfusion",
            "volume": "46",
            "issn": "",
            "pages": "1168-1177",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF17": {
            "title": "Inactivation of parvovirus B19 in human platelet concentrates by treatment with Amotosalen and ultraviolet A illumination",
            "authors": [
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Sawyer",
                    "suffix": ""
                },
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Hanson",
                    "suffix": ""
                },
                {
                    "first": "G.",
                    "middle": [],
                    "last": "Castro",
                    "suffix": ""
                },
                {
                    "first": "W.",
                    "middle": [],
                    "last": "Luckett",
                    "suffix": ""
                },
                {
                    "first": "T.W.",
                    "middle": [],
                    "last": "Dubensky",
                    "suffix": "Jr."
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Stassinopoulos",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Transfusion",
            "volume": "47",
            "issn": "",
            "pages": "1062-1070",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF18": {
            "title": "Efficacy of INTERCEPT Treatment for the Inactivation of Dengue Virus in Single-Donor Platelet Concentrate",
            "authors": [
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Lam",
                    "suffix": ""
                },
                {
                    "first": "H.C.",
                    "middle": [],
                    "last": "Tan",
                    "suffix": ""
                },
                {
                    "first": "L.K.",
                    "middle": [],
                    "last": "Tan",
                    "suffix": ""
                },
                {
                    "first": "L.C.",
                    "middle": [],
                    "last": "Ng",
                    "suffix": ""
                },
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Teo",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Koh",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Transfusion",
            "volume": "47",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF19": {
            "title": "Photochemical inactivation with Amotosalen and long-wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components",
            "authors": [
                {
                    "first": "P.",
                    "middle": [],
                    "last": "Grellier",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Benach",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Labaied",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Charneau",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Gil",
                    "suffix": ""
                },
                {
                    "first": "G.",
                    "middle": [],
                    "last": "Monsalve",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Transfusion",
            "volume": "48",
            "issn": "",
            "pages": "1676-1684",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF20": {
            "title": "Inactivation of Influenza A H5N1 and Lymphocytic Choriomeningitis Virus by the INTERCEPT Blood System (IBS)",
            "authors": [
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Sawyer",
                    "suffix": ""
                },
                {
                    "first": "K.",
                    "middle": [],
                    "last": "Dupuis",
                    "suffix": ""
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Sampson-Johannes",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Transfusion",
            "volume": "48",
            "issn": "2S",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF21": {
            "title": "The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends",
            "authors": [
                {
                    "first": "R.P.",
                    "middle": [],
                    "last": "Goodrich",
                    "suffix": ""
                },
                {
                    "first": "R.A.",
                    "middle": [],
                    "last": "Edrich",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Seghatchian",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Transfus Apher Sci",
            "volume": "35",
            "issn": "",
            "pages": "5-17",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF22": {
            "title": "Pathogen inactivation: making decisions about new technologies. Report of a consensus conference",
            "authors": [
                {
                    "first": "H.G.",
                    "middle": [],
                    "last": "Klein",
                    "suffix": ""
                },
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Anderson",
                    "suffix": ""
                },
                {
                    "first": "M.J.",
                    "middle": [],
                    "last": "Bernardi",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Cable",
                    "suffix": ""
                },
                {
                    "first": "W.",
                    "middle": [],
                    "last": "Carey",
                    "suffix": ""
                },
                {
                    "first": "J.S.",
                    "middle": [],
                    "last": "Hoch",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Transfusion",
            "volume": "47",
            "issn": "",
            "pages": "2338-2347",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF23": {
            "title": "Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light",
            "authors": [
                {
                    "first": "P.H.",
                    "middle": [],
                    "last": "Ruane",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Edrich",
                    "suffix": ""
                },
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Gampp",
                    "suffix": ""
                },
                {
                    "first": "S.D.",
                    "middle": [],
                    "last": "Keil",
                    "suffix": ""
                },
                {
                    "first": "R.L.",
                    "middle": [],
                    "last": "Leonard",
                    "suffix": ""
                },
                {
                    "first": "R.P.",
                    "middle": [],
                    "last": "Goodrich",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Transfusion",
            "volume": "44",
            "issn": "",
            "pages": "877-885",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF24": {
            "title": "Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products",
            "authors": [
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "D.",
                    "middle": [],
                    "last": "de Korte",
                    "suffix": ""
                },
                {
                    "first": "M.D.",
                    "middle": [],
                    "last": "Woolum",
                    "suffix": ""
                },
                {
                    "first": "P.H.",
                    "middle": [],
                    "last": "Ruane",
                    "suffix": ""
                },
                {
                    "first": "S.D.",
                    "middle": [],
                    "last": "Keil",
                    "suffix": ""
                },
                {
                    "first": "O.",
                    "middle": [],
                    "last": "Lockerbie",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Vox Sang",
            "volume": "87",
            "issn": "",
            "pages": "82-90",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF25": {
            "title": "Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light",
            "authors": [
                {
                    "first": "L.J.",
                    "middle": [],
                    "last": "Cardo",
                    "suffix": ""
                },
                {
                    "first": "F.J.",
                    "middle": [],
                    "last": "Rentas",
                    "suffix": ""
                },
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Ketchum",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Salata",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Harman",
                    "suffix": ""
                },
                {
                    "first": "W.",
                    "middle": [],
                    "last": "Melvin",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Vox Sang",
            "volume": "90",
            "issn": "",
            "pages": "85-91",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF26": {
            "title": "Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light",
            "authors": [
                {
                    "first": "L.J.",
                    "middle": [],
                    "last": "Cardo",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Salata",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Mendez",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Reddy",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Goodrich",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Transfus Apher Sci",
            "volume": "37",
            "issn": "",
            "pages": "131-137",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF27": {
            "title": "Inactivation of Orientia tsutsugamushi in red blood cells, plasma, and platelets with riboflavin and light, as demonstrated in an animal model",
            "authors": [
                {
                    "first": "F.",
                    "middle": [],
                    "last": "Rentas",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Harman",
                    "suffix": ""
                },
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Gomez",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Salata",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Childs",
                    "suffix": ""
                },
                {
                    "first": "T.",
                    "middle": [],
                    "last": "Silva",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Transfusion",
            "volume": "47",
            "issn": "",
            "pages": "240-247",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF28": {
            "title": "Methylene blue-treated fresh frozen plasma: whath is its the contribution to blood safety?",
            "authors": [
                {
                    "first": "L.M.",
                    "middle": [],
                    "last": "Williamson",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Cardigan",
                    "suffix": ""
                },
                {
                    "first": "C.V.",
                    "middle": [],
                    "last": "Prowse",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Transfusion",
            "volume": "43",
            "issn": "",
            "pages": "1322-1329",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF29": {
            "title": "Influence of methylene blue photoinactivation treatment on coagulation factors from Fresh Frozen Plasma, cryoprecipitates and cryosupernatants",
            "authors": [
                {
                    "first": "J.A.",
                    "middle": [],
                    "last": "Aznar",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Bonanad",
                    "suffix": ""
                },
                {
                    "first": "J.M.",
                    "middle": [],
                    "last": "Montoro",
                    "suffix": ""
                },
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Hurtado",
                    "suffix": ""
                },
                {
                    "first": "A.R.",
                    "middle": [],
                    "last": "Cid",
                    "suffix": ""
                },
                {
                    "first": "M.A.",
                    "middle": [],
                    "last": "Soler",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Vox Sang",
            "volume": "79",
            "issn": "",
            "pages": "156-160",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF30": {
            "title": "Photoinactivation of viruses in human Fresh Frozen Plasma by phenothiazine dyes in combination with visible light",
            "authors": [
                {
                    "first": "B.",
                    "middle": [],
                    "last": "Lambrecht",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Mohr",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Kn\u00fcver-Hopf",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Schmitt",
                    "suffix": ""
                }
            ],
            "year": 1991,
            "venue": "Vox Sang",
            "volume": "60",
            "issn": "",
            "pages": "207-213",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF31": {
            "title": "No evidence for neoantigens in human plasma after photochemical virus inactivation",
            "authors": [
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Mohr",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Kn\u00fcver-Hopf",
                    "suffix": ""
                },
                {
                    "first": "B.",
                    "middle": [],
                    "last": "Lambrecht",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Scheidecker",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Schmitt",
                    "suffix": ""
                }
            ],
            "year": 1992,
            "venue": "Ann Hematol",
            "volume": "65",
            "issn": "",
            "pages": "224-228",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF32": {
            "title": "The effect of methylene blue-phototreatment on plasma proteins and in vitro coagulation capability of single-donor Fresh Frozen Plasma",
            "authors": [
                {
                    "first": "T.",
                    "middle": [],
                    "last": "Zeiler",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Riess",
                    "suffix": ""
                },
                {
                    "first": "G.",
                    "middle": [],
                    "last": "Wittman",
                    "suffix": ""
                },
                {
                    "first": "G.",
                    "middle": [],
                    "last": "Hintz",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Zimmermenn",
                    "suffix": ""
                },
                {
                    "first": "C.",
                    "middle": [],
                    "last": "M\u00fcller",
                    "suffix": ""
                }
            ],
            "year": 1994,
            "venue": "Transfusion",
            "volume": "34",
            "issn": "",
            "pages": "685-689",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF33": {
            "title": "Safety of the blood supply: role of pathogen reduction",
            "authors": [
                {
                    "first": "Y.Y.",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "E.L.",
                    "middle": [],
                    "last": "Snyder",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Blood Rev",
            "volume": "17",
            "issn": "",
            "pages": "111-122",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF34": {
            "title": "Factor VIII/von Willebrand factor complex in methylene blue-treated fresh plasm",
            "authors": [
                {
                    "first": "J.A.",
                    "middle": [],
                    "last": "Aznar",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Molina",
                    "suffix": ""
                },
                {
                    "first": "J.M.",
                    "middle": [],
                    "last": "Montoro",
                    "suffix": ""
                }
            ],
            "year": 1999,
            "venue": "Transfusion",
            "volume": "39",
            "issn": "",
            "pages": "748-750",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF35": {
            "title": "Filtration of methylene blue\u2013photooxidized plasma: influence on coagulation and cellular contamination",
            "authors": [
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Riggert",
                    "suffix": ""
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Humpe",
                    "suffix": ""
                },
                {
                    "first": "T.J.",
                    "middle": [],
                    "last": "Legler",
                    "suffix": ""
                },
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Wolf",
                    "suffix": ""
                },
                {
                    "first": "G.",
                    "middle": [],
                    "last": "Simson",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "K\u00f6hler",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "Transfusion",
            "volume": "41",
            "issn": "",
            "pages": "82-86",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF36": {
            "title": "Impact of quarantine and methylene blue/light treatment on plasma quality",
            "authors": [
                {
                    "first": "E.",
                    "middle": [],
                    "last": "Castro",
                    "suffix": ""
                },
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Barea",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Gonzalez",
                    "suffix": ""
                },
                {
                    "first": "J.L.",
                    "middle": [],
                    "last": "Bueno",
                    "suffix": ""
                }
            ],
            "year": 1998,
            "venue": "Transfusion",
            "volume": "38",
            "issn": "Suppl",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF37": {
            "title": "Evaluation of methylene blue treated plasma",
            "authors": [
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Castrillo",
                    "suffix": ""
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Eiras",
                    "suffix": ""
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Casro",
                    "suffix": ""
                },
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Areal",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Adelantado",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Cid",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Vox Sang",
            "volume": "78",
            "issn": "Suppl 1",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF38": {
            "title": "A potential improved approach to methylene blue virus inactivation of plasma: the Maco Pharma Maco-tronic system",
            "authors": [
                {
                    "first": "V.",
                    "middle": [],
                    "last": "Hornsey",
                    "suffix": ""
                },
                {
                    "first": "O.",
                    "middle": [],
                    "last": "Dummond",
                    "suffix": ""
                },
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Young",
                    "suffix": ""
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Docherty",
                    "suffix": ""
                },
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Prowse",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Vox Sang",
            "volume": "78",
            "issn": "Suppl 1",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF39": {
            "title": "Elimination of methylene blue from photo-dynamically treated virus inactivated fresh-frozen plasma: the Bluflex filter",
            "authors": [
                {
                    "first": "T.",
                    "middle": [],
                    "last": "Verpoort",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Chollet",
                    "suffix": ""
                },
                {
                    "first": "F.",
                    "middle": [],
                    "last": "Lebrun",
                    "suffix": ""
                },
                {
                    "first": "F.",
                    "middle": [],
                    "last": "Goudalier",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Mohr",
                    "suffix": ""
                },
                {
                    "first": "W.H.",
                    "middle": [],
                    "last": "Walker",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "Transfus Clin Biol",
            "volume": "8",
            "issn": "Suppl 1",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF40": {
            "title": "What's happening: the quality of methylene blue treated",
            "authors": [
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Seghatchian",
                    "suffix": ""
                },
                {
                    "first": "P.",
                    "middle": [],
                    "last": "Krailadsiri",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "Transfus Apher Sci",
            "volume": "25",
            "issn": "",
            "pages": "227-231",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF41": {
            "title": "A new evaluation of methylene blue treated plasma",
            "authors": [
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Castrillo",
                    "suffix": ""
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Eiras",
                    "suffix": ""
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Castro",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Adelantado",
                    "suffix": ""
                },
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Areal",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Cid",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "Transfus Clin Biol",
            "volume": "8",
            "issn": "Suppl. 1",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF42": {
            "title": "Comparison of von Willebrand factor antigen, von Willebrand factor-cleacing protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura",
            "authors": [
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Yarranton",
                    "suffix": ""
                },
                {
                    "first": "A.S.",
                    "middle": [],
                    "last": "Lawrie",
                    "suffix": ""
                },
                {
                    "first": "G.",
                    "middle": [],
                    "last": "Purdy",
                    "suffix": ""
                },
                {
                    "first": "I.J.",
                    "middle": [],
                    "last": "Mackie",
                    "suffix": ""
                },
                {
                    "first": "S.J.",
                    "middle": [],
                    "last": "Machin",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Transfus Med",
            "volume": "14",
            "issn": "",
            "pages": "39-44",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF43": {
            "title": "The six questions of pathogen reduction technology: An overview of current opinions",
            "authors": [
                {
                    "first": "G.",
                    "middle": [],
                    "last": "Solheim",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Seghatchian",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Transfus Apher Sci",
            "volume": "39",
            "issn": "",
            "pages": "51-57",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF44": {
            "title": "The hazards of blood transfusion in historical perspective",
            "authors": [
                {
                    "first": "H.J.",
                    "middle": [],
                    "last": "Alter",
                    "suffix": ""
                },
                {
                    "first": "H.G.",
                    "middle": [],
                    "last": "Klein",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Blood",
            "volume": "112",
            "issn": "",
            "pages": "2617-2626",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF45": {
            "title": "Pathogen reduction of blood components",
            "authors": [
                {
                    "first": "G.",
                    "middle": [],
                    "last": "Solheim",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Transfus Apher Sci",
            "volume": "39",
            "issn": "",
            "pages": "75-82",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF46": {
            "title": "Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: methylene blue and Amotosalen",
            "authors": [
                {
                    "first": "J.C.",
                    "middle": [],
                    "last": "Osselaer",
                    "suffix": ""
                },
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Debry",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Goffaux",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Pineau",
                    "suffix": ""
                },
                {
                    "first": "G.",
                    "middle": [],
                    "last": "Calomme",
                    "suffix": ""
                },
                {
                    "first": "E.",
                    "middle": [],
                    "last": "Dubuc",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Transfusion",
            "volume": "48",
            "issn": "",
            "pages": "108-117",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF47": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF48": {
            "title": "In vitro evaluation of pooled buffy coat platelets treated with photochemical pathogen inactivation using Amotosalen",
            "authors": [
                {
                    "first": "J.P.",
                    "middle": [],
                    "last": "Cazenave",
                    "suffix": ""
                },
                {
                    "first": "B.",
                    "middle": [],
                    "last": "Aleil",
                    "suffix": ""
                },
                {
                    "first": "M.L.",
                    "middle": [],
                    "last": "Wiesel",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Lafor\u00eat",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Isola",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Vox Sang",
            "volume": "86",
            "issn": "",
            "pages": "201-202",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF49": {
            "title": "Functional characteristics of buffy-coat PLTs photochemically treated with Amotosalen-HCl for pathogen inactivation",
            "authors": [
                {
                    "first": "S.M.",
                    "middle": [],
                    "last": "Picker",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Speer",
                    "suffix": ""
                },
                {
                    "first": "B.S.",
                    "middle": [],
                    "last": "Gathof",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Transfusion",
            "volume": "44",
            "issn": "",
            "pages": "320-329",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF50": {
            "title": "Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets",
            "authors": [
                {
                    "first": "K.",
                    "middle": [],
                    "last": "Janetzko",
                    "suffix": ""
                },
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Lin",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Eichler",
                    "suffix": ""
                },
                {
                    "first": "V.",
                    "middle": [],
                    "last": "Mayaudon",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Flament",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Kl\u00fcter",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Vox Sang",
            "volume": "86",
            "issn": "",
            "pages": "239-245",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF51": {
            "title": "Functional characteristics of photochemically treated platelets",
            "authors": [
                {
                    "first": "G.A.",
                    "middle": [],
                    "last": "Jansen",
                    "suffix": ""
                },
                {
                    "first": "H.H.",
                    "middle": [],
                    "last": "van Vliet",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Vermeij",
                    "suffix": ""
                },
                {
                    "first": "E.A.",
                    "middle": [],
                    "last": "Beckers",
                    "suffix": ""
                },
                {
                    "first": "F.W.",
                    "middle": [],
                    "last": "Leebeek",
                    "suffix": ""
                },
                {
                    "first": "P.",
                    "middle": [],
                    "last": "Sonneveld",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Transfusion",
            "volume": "44",
            "issn": "",
            "pages": "313-319",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF52": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF53": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF54": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF55": {
            "title": "Reducing the infectivity of blood components. What we have learned",
            "authors": [
                {
                    "first": "L.I.",
                    "middle": [],
                    "last": "Friedman",
                    "suffix": ""
                },
                {
                    "first": "R.R.",
                    "middle": [],
                    "last": "Stromberg",
                    "suffix": ""
                },
                {
                    "first": "S.J.",
                    "middle": [],
                    "last": "Wagner",
                    "suffix": ""
                }
            ],
            "year": 1995,
            "venue": "Immunol Invest",
            "volume": "24",
            "issn": "",
            "pages": "49-71",
            "other_ids": {
                "DOI": []
            }
        }
    }
}